ZyVersa Therapeutics, Inc. (ZVSA)
OTCMKTS · Delayed Price · Currency is USD
0.1050
-0.0110 (-9.48%)
At close: Jul 30, 2026
ZyVersa Therapeutics Ratios and Metrics
Market cap in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Quarter | Current | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 29, 2026 | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Sep '25 Sep 30, 2025 | Jun '25 Jun 30, 2025 | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Sep '24 Sep 30, 2024 | Jun '24 Jun 30, 2024 | Mar '24 Mar 31, 2024 | Dec '23 Dec 31, 2023 | Sep '23 Sep 30, 2023 | Jun '23 Jun 30, 2023 | Mar '23 Mar 31, 2023 | Dec '22 Dec 31, 2022 | Sep '22 Sep 30, 2022 | Jun '22 Jun 30, 2022 | Mar '22 Mar 31, 2022 | Dec '21 Dec 31, 2021 | Sep '21 Sep 30, 2021 | Jun '21 Jun 30, 2021 |
| 1 | 2 | 1 | 1 | 3 | 2 | 3 | 3 | 3 | 6 | 5 | 6 | 6 | 18 | 14 | 100 | 100 | 96 | - | - | - | |
Market Cap Growth (YoY) | -48.48% | 0.30% | -59.32% | -53.84% | 5.12% | -71.66% | -43.66% | -54.25% | -45.97% | -67.96% | -66.90% | -94.38% | -94.17% | -81.56% | - | - | - | - | - | - | - |
Enterprise Value | 2 | 2 | 1 | 1 | 2 | 0 | 3 | 2 | 1 | 3 | 3 | 5 | 5 | 12 | 18 | 109 | - | - | - | - | - |
Last Close Price | 0.10 | 0.20 | 0.13 | 0.15 | 0.68 | 0.63 | 1.06 | 2.40 | 3.76 | 7.50 | 9.00 | 45.33 | 85.93 | 675.50 | 549.50 | 3496.50 | 3475.50 | 3482.50 | - | - | - |
PE Ratio | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -1.01 | - | - | - | - | - | - |
PB Ratio | -0.06 | -0.11 | -0.09 | -0.10 | 0.54 | 0.20 | 0.31 | 0.37 | 0.36 | 0.51 | 0.43 | 0.29 | 0.29 | 0.18 | 0.14 | -8.26 | -6.40 | -6.77 | - | - | - |
Debt / Equity Ratio | -0.08 | -0.08 | - | - | - | - | - | - | - | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.33 | -0.59 | -0.64 | -0.71 | - | - |
Net Debt / Equity Ratio | -0.06 | -0.06 | 0.01 | 0.05 | -0.01 | -0.20 | -0.18 | -0.02 | -0.01 | -0.18 | -0.28 | -0.08 | -0.01 | -0.01 | -0.06 | -0.28 | -0.59 | -0.62 | -0.69 | - | - |
Net Debt / EBITDA Ratio | - | - | 0.02 | 0.07 | 0.01 | 0.19 | 0.17 | 0.01 | 0.01 | 0.16 | 0.22 | 0.09 | 0.01 | 0.08 | 0.42 | -0.32 | -1.00 | -0.97 | -1.15 | - | - |
Quick Ratio | 0.02 | 0.02 | 0.01 | 0.04 | 0.01 | 0.13 | 0.14 | 0.01 | 0.01 | 0.21 | 0.31 | 0.14 | 0.02 | 0.15 | 0.72 | 0.04 | 0.00 | 0.02 | 0.02 | - | - |
Current Ratio | 0.05 | 0.05 | 0.03 | 0.08 | 0.04 | 0.18 | 0.15 | 0.03 | 0.06 | 0.30 | 0.33 | 0.17 | 0.11 | 0.33 | 0.78 | 0.16 | 0.10 | 0.08 | 0.06 | - | - |
Return on Equity (ROE) | - | - | - | -124.32% | -108.46% | -73.17% | -122.77% | -111.42% | -101.42% | -346.70% | -58.39% | -536.11% | -14.41% | -42.75% | - | - | - | - | - | - | |
Return on Assets (ROA) | -598.42% | -198.77% | -50.87% | -25.16% | -25.79% | -16.07% | -29.18% | -33.49% | -32.29% | -16.16% | -22.38% | -17.52% | -9.84% | -21.46% | -396.43% | -273.80% | -640.50% | - | - | - | |
Return on Capital Employed (ROCE) | 42.50% | 42.50% | 55.30% | 64.60% | -111.40% | -94.10% | -97.50% | -122.10% | -108.30% | -104.90% | -121.00% | -84.30% | -85.20% | -14.20% | -12.50% | 88.30% | 60.10% | 65.50% | 61.60% | - | - |
Earnings Yield | -2994.89% | -1512.42% | -2306.96% | -2159.11% | -251.26% | -547.81% | -354.06% | -827.37% | -695.44% | -1713.12% | -2083.02% | -1590.65% | -1556.36% | -78.29% | -99.05% | -11.39% | -9.64% | -10.05% | - | - | - |
Buyback Yield / Dilution | -316.62% | -160.58% | -308.95% | -683.17% | -476.60% | -398.23% | -826.75% | -916.31% | -1536.54% | -2291.01% | 99.77% | -40.84% | 26.11% | 62.23% | -867.65% | - | - | - | - | - | - |